
Critical Path Institute Announces New Board Members Bonnie A. Allin and Louis Breton

Allin and Breton join C-Path Board of Directors to support strategic vision

TUCSON, Ariz., April 10, 2024 — Critical Path Institute (C-Path) today announced the appointments of Bonnie A. Allin and Louis Breton to its Board of Directors. Allin and Breton will lend their considerable expertise and experience to guide the strategic vision and mission of the nonprofit organization, as it continues its work to accelerate the development of treatments and cures for diseases with unmet needs.

Bonnie A. Allin, with a storied career in the aviation industry, provides C-Path a wealth of experience in strategic planning and leadership. Having retired as President & CEO of the Tucson Airport Authority in 2019, Allin has since been dedicated to leveraging her knowledge for the betterment of various organizations through advisory roles. Her tenure in the aviation industry, distinguished by numerous achievements and accolades, reflects her dedication to outstanding performance and community engagement.



Louis Breton,
CEO and co-
founder of
Rampart
Bioscience,

adds to the board a rich background in biotechnology and life sciences leadership. Breton's experience in founding and leading Calimmune, a gene therapy company focused on chronic and currently incurable diseases, highlights his innovative approach to biotechnology and his commitment to advancing medical science. His involvement in over 20 product launches, alongside numerous licensing deals and regulatory negotiations, showcases a track record of success and impact in the field.

“Welcoming Bonnie A. Allin and Louis Breton to the Board of Directors is a significant step forward for C-Path,” said M. Wainright Fishburn Jr., C-Path Board Chairman. “Their diverse backgrounds and depth of experience will be invaluable as we seize the opportunities ahead, with the aim of enhancing our global impact on healthcare and treatment development.”

Allin expressed her enthusiasm about joining C-Path, highlighting the organization's crucial role in improving the drug development process. “I am eager to contribute to C-Path's mission, which resonates deeply with my personal and professional values,” she said.

Breton also shared his anticipation of contributing to C-Path's efforts, stating, "Joining C-Path's Board is a great privilege. I am especially excited about lending my experience to the organization's innovative projects that have the potential to significantly advance patient care."

Both Allin and Breton's appointments are effective immediately, promising to bring fresh perspectives and dedicated leadership to C-Path's ongoing and future initiatives.

For more information about C-Path and its mission, visit c-path.org and like and follow on [LinkedIn](#), [Facebook](#), [Threads](#) and [X](#).

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the [FDA's Critical Path Initiative](#). C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling \$19,436,549, and 46% funded by non-government source(s), totaling \$16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

Contacts:

Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org

Kissy Black
C-Path
615.310.1894
kblack@c-path.org